Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Durvalumab in Pre-treated Extensive Stage SCLC
NCT05572476Phase 2Withdrawn
- Sponsor
- Institut Bergonié
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin, durvalumab in small cell lung cancer (SCLC), sponsored by Institut Bergonié. Planned start Oct 2023; status: withdrawn.
02
Drugs
lurbinectedindurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05572476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572476.